

Chicago-based Multicenter Endophthalmitis Registry: **Initial Loyola University Medical Center Data**

Shivan Tekwani, M.D., Felipe de Alba M.D., Mark Daily M.D., Charles Bouchard, M.D., Bruce Gavnes, O.D., Pharm D Department of Ophthalmology, Lovola University Health System, Maywood, IL,

Methods

Introduction

Endophthalmitis is a rare, but devastating outcome after intraocular surgery, trauma, systemic or local infection. It is characterized by inflammation involving the vitreous cavity and the anterior chamber of the eye. Once suspected, patients are subjected to ocular tissue biopsies, with microbial cultures, antibiotics delivered in multiple routes, and sometimes surgery to remove the vitreous gel. Often the patients end up with profound and permanent vision loss.

The prevalence of endophthalmitis has been studied for several etiologies. The prevalence of endophthalmitis post-cataract surgery was found to be approximately 0.1%.[1] [2] [3] It was highest after secondary intraocular lens placement (0.366%) and corneal transplant surgery (0.178%) and lowest after vitrectomy (0.045%).[2] A recent study looked compared the two most common anti-VEGF agents and found a low endophthalmitis rate of 0.02%.[4] World-wide prevalence rates vary slightly, but for postcataract surgery endophthalmitis the rates seem to be <0.2%.[5] [6] The most common organisms isolated after cataract surgery are coagulasenegative staphylococci, up to 70%.[2] [7]

Endophthalmitis can result from extension of local infection, such as a corneal ulcer, or from endogenous spread.[1] Endogenous bacterial endophthalmitis develops acutely, caused by streptococcus species from endocarditis, Staphylococcus aureus from cutaneous infections, and Bacillus from IV drug use.[8] [9] Fungal endogenous endophthalmitis is the most common form of endogenous endophthalmitis. Candidemia is the most common cause.[8] Posttraumatic endophthalmitis is the most prevalent at 3-17%.[10] [11] The most common organisms isolated are staphylococcus species and Bacillus cereus.[1] The prevalence may have a wide range due to several risk factors, including contamination, retained foreign body, location/extent of laceration, time to closure, or

globe rupture with extrusion of intraocular

contents

Introduction

Endopthalmitis is suspected in a patient presenting with an ocular history aforementioned and symptoms of eve redness, pain, blurry vision. On exam patients often have injection, anterior chamber inflammation and vitritis. Once suspected, anterior or posterior chamber cultures are obtained. The Endophthalmitis Vitrectomy Study (EVS) studied the management of endophthalmitis with vitrectomy surgery, recommending vitrectomy surgery for end point visual outcome in patients with vision of no better than light perception.[12] [13] This data also helped determine antibiotic treatment strategies, and commonly used antibiotics are vancomycin and ceftazidime.[14] Treatment is delivered intravitreal. IV, oral, and/or topical. As ocular tissue destruction from endophthalmitis is largely due to the significant inflammatory process, steroids are used by some ophthalmologists routinely, but its use is controversial. Visual outcome will depend on several factors, such as etiology of endophthalmitis, trauma risk factors previously mentioned, virulence of organism, and host inflammatory response.

The goal of the project is to create a data repository of local cases of endophthalmitis from several large Chicago-area academic and private institutions. Once the registry is created we will be able to analyze the wealth of data and draw connections and common trends across the institutions. Different institution practices and management can be looked at and correlate with visual outcome to help determine an optimal course of treatment. We can determine the common infecting microorganisms in endophthalmitis in this area, which may direct treatment strategies and ultimately save patients' vision due to the importance of timely diagnosis and treatment.

Loyola University Medical Center will be the lead site for the study, and data gathered from other institutions will be sent to the Lovola primary investigators for compilation and subsequent analysis. The initial data presented here represents Loyola patients diagnosed with endophthalmitis since the initiation of EPIC medical records.

This project is intended to be part of a Chicago-area ophthalmology consortium, with the intended purpose of gathering valuable data from the large pool of patients throughout several of Chicago's large academic and private institutions. Patients with endophthalmitis of all ages, ethnicity, and sex will be sought, and the time period will cover 10 years- from July 1st 1999 to June 30th, 2009. Exclusion criteria include any later change in the diagnosis of endophthalmitis. Search Criteria

Patients matching the inclusion criteria are determined through a retrospective chart review search of the institution's medical record system using diagnostic ICD-9 codes for various types of endophthalmitis

The form details patients' history, including inciting etiology of endophthalmitis, and symptoms- eye pain, vision changes, and exam findings. Pertinent exam findings include vision pre-op, post-op/post-trauma vision, vision at diagnosis of endophthamitis, and vision 6 months following diagnosis. Other initial exam findings are noted.

Diagnosis and management will be recorded. Data is collected on method of diagnosis- anterior chamber and/or vitreous tap for culture or vitrectomy. Results of cultures are an important component of the data, specifically what organism grew as well as antibiotic sensitivities. Medications used to treat the patients will be documented- topical, intravitreal, intravenous, oral antibiotics and any steroid use. The goal of the form is to provide as much data about each patient's case as possible to give depth to the data repository.

Graph or image title

Results

7 patients have been identified thus far. The ages ranged from 23-81, median 47, with 4 males and 3 females. Of the 3 patients that had post- cataract surgery endophthalmitis. 2 had post-surgical complications of lens capsule tear, and 1 of these underwent a vitrectomy to remove lens material the same day. Only one of these patients grew an organism: Propionibacterium acnes. All 3 had vitrectomy and all 3 retained good vision (2/3 >20/40, 1/3 with 20/60) after being treated with vancomycin +/- ceftazidime intravitreally. 3 patients had endogenous endophthalmitis. Each were immunocompromised- 2 with leukemia, 1 post lung transplant for cystic fibrosis. All three were clinical diagnoses based on blood or lung culture. Organisms suspected were Aspergillus and Candida albicans and glabrata. All three expired (two within 1 mo, the third had resolution of infection with IV antifungals but subsequently expired within 1 year). We were unable to assess vision in these critically ill patients. The last patient had Streptococcus viridans endophthalmitis after an intravitreal Avastin injection to treat a fluid leak from a neovascular membrane beneath the retina. She had a poor visual outcome, but not significantly different than before the onset of endophthalmitis.

Conclusion

From the initial Loyola Data, the most common etiologies of endophthalmitis are post-cataract surgery and endogenous. The post-cataract surgery patients retained good vision, whereas the eye findings in the immunocompromised endogenous endophthalmmitis patients reflected their critical health conditions. Endogenous cases are more likely to be diagnosed clinically and from blood cultures rather than anterior chamber or vitreous tap/biopsies. Standard treatment of intravitreal vancomycin/ceftazidime was initiated in the post-cataract and post-avastin injection patients, but treatment was systemic with antifungals for the cases of fungal endophthalmitis. Subsequent data will be collected from Loyola with an estimated 25 cases, and added from other Chicago-area academic and private centers.

References

[1] Callegan MC, Engelbert M, Parke DW et al. Bacterial Endophthalmitis: Epidemiology, Therapeutics, and Bacterium-Host Interactions. Clinical Microbiology Reviews. 2002; 15(1):111-24 [2] Aaberg TM Jr, Flynn HW Jr, Schiffman J, et al. Nosocomial Acuteonset Postoperative Endophthalmitis Survey: A 10-year Review of Incidence and Outcomes. Ophthalmology. 1998; 105(6):1004-10 [3] Javitt JC, Street DA, Tielsch JM et al. National Outcomes of cataract extraction. Retinal detachment and endophthalmitis after outpatient cataract surgery. Ophthalmology 1994; 101: 100-6 [4] Fintak DR, Shah GK, Blinder KJ, et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retinal 2008. 28(10):1395-9 [5] Kamalarajah S, Silvestri G, Sharma N, et al. Surveillance of endophthalmitis following cataract surgery in the UK. Eye. 2004; 18:580-

[6] Lundstrom M, Wejde G, Stenevi U, et al. Endophthalmitis after Cataract Surgery: A Nationwide Prospective Study Evaluating Incidence in Relation to Incision Type and Location. Ophthalmology 2007:114(5):866-870

[7] Han DP, Wisniewski SR, Wilson LA, et al. Spectrum and Susceptibilities of microbiological isolates in the Endophthalmitis Vitrectomy Study. Am J Ophthalmol. 1996; 122:1-17 [8] Basic and Clinical Science Course: Section 9- Intraocular Inflammation and Uveitis. American Academy of Ophthalmology. 2006-

2007: 213-4 [9] Okada AA, Johnson RP, Liles WC, et al. Endogenous bacterial endophthalmitis: report of a ten-year retrospective study.

Ophthalmology. 1994; 28:185-94 [10] Meredith TA. Posttraumatic endophthalmitis. Arch Ophthalmol. 1999 117 520-1

[11] O'Brien TP, Choi S. Trauma-related ocular infections. Int Ophthalmol Clin N Am. 1995; 8:667-79 [12] Endophthalmitis Vitrectomy Study, A randomized trial of immediate vitrectomy and of intravitreous antibiotics for the treatment of

postoperative bacterial endophthalmitis. Arch Ophthalmol. 1995; 113 1479-96 [13] Endophthalmitis Vitrectomy Study. Microbiological factors and

visual outcome in the Endophthalmitis Vitrectomy Study. Am J Ophthalmol 1996: 830-46

[14] Aaberg, Flynn HW Jr, Murray. Intraocular ceftazidime as an alternative to the amnioglycosides in the treatment of endophthalmitis. Arch Ophthalmol. 1994; 112:18-9

Acknowledgement: This work was supported by the Richard A. Perritt Charitable Foundation.